NCC, PREMIA, Paradigm unveil nationwide clinical trial network in Japan

The LC-SCRUM-CD serves as an expansion of the LC-SCRUM-Asia network.

The National Cancer Centre (NCC), Precision Medicine Asia Co., Ltd. (PREMIA) and Paradigm Health Inc., have announced the launch of the Lung Cancer Genome Screening Project for Individualised Medicine - Clinical Development (LC-SCRUM-CD).

In a statement, the initiative serves as a nationwide clinical trial network that will leverage the cancer genomic screening network that comprises over 150 LC-SCRUM-Asia hospitals to promote precision medicine.

The LC-SCRUM-CD, an expansion of the LC-SCRUM-Asia network, is intended to streamline clinical trial enrolment processes and improve patient’s access to these trials.